ArticlePharmaceuticals (Basel, Switzerland)2022

A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile.

Wei Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.